Microglial H3K18 Lactylation Protects White Matter After ICH

Study Background and Research Question

White matter injury (WMI) is a principal determinant of long-term cognitive impairment after intracerebral hemorrhage (ICH), yet the underlying mechanisms remain unclear and effective interventions are lacking. Recent research has shifted focus from acute neuronal damage and inflammation to metabolic and epigenetic reprogramming within the brain. In particular, the accumulation of lactate in perihematomal regions post-ICH has attracted attention for its roles beyond metabolism, including as a substrate for histone lactylation—a post-translational modification implicated in gene regulation and neuroprotection. The current study, "Inhibiting H3K18 lactylation in microglia aggravates white matter injury after intracerebral hemorrhage in mice", investigates whether microglial H3K18 lactylation, a specific histone modification, influences WMI and cognitive recovery after ICH, and explores the upstream metabolic and epigenetic pathways involved.

Key Innovation from the Reference Study

The central innovation of this work lies in unraveling a lactate-p300/CBP-H3K18la axis as a critical endogenous neuroprotective mechanism in post-ICH white matter repair. Unlike prior studies that predominantly treated lactate as a metabolic byproduct or energy substrate, this research establishes a direct link between lactate-derived histone H3K18 lactylation in microglia and the preservation of white matter integrity. By distinguishing between the effects of metabolic inhibition of lactate production and targeted suppression of histone lactylation, the study clarifies the unique, non-redundant role of epigenetic lactylation in brain recovery following hemorrhagic injury.

Methods and Experimental Design Insights

The investigators utilized a well-established collagenase-induced ICH mouse model to mimic clinical brain hemorrhage. To dissect the mechanism, they employed a combination of pharmacological inhibitors and cell depletion strategies:

• LDH-A inhibition: Sodium oxamate (Oxamic Acid), a classical competitive inhibitor of lactate dehydrogenase A (LDH-A), was used to suppress glycolytic lactate production.
• p300/CBP inhibition: A-485, a selective p300/CBP histone acetyltransferase inhibitor, targeted the epigenetic writer responsible for H3K18 lactylation.
• Microglia depletion: PLX5622, a CSF1R inhibitor, was administered to ablate microglia and assess the cell-specific contribution of the pathway.

Time-course analyses were performed to track H3K18la expression and oligodendrocyte precursor cell (OPC) recruitment at multiple post-injury intervals (days 3, 7, 14, 21). White matter integrity was evaluated using immunostaining for myelin basic protein (MBP) and neurofilament H (SMI32), supplemented by transmission electron microscopy. Cognitive outcomes were assessed up to 28 days post-ICH via the Morris Water Maze. The multifaceted approach allowed for a nuanced dissection of metabolic, epigenetic, and cellular contributions to WMI and recovery.

Protocol Parameters

• Intracerebral hemorrhage (ICH) model: Collagenase injection in mouse striatum to induce localized hemorrhage.
• Sodium oxamate administration: Dosage and timing in line with established protocols for LDH-A inhibition; specific regimens reproducible according to recent workflow guides.
• A-485 administration: Systemic delivery at doses validated for central p300/CBP inhibition, started post-ICH to interrogate epigenetic modulation.
• PLX5622 treatment: Dietary administration initiated prior to ICH for effective microglial depletion.
• White matter analysis: MBP and SMI32 immunostaining, quantification of OPCs, and ultrastructural assessment via electron microscopy.
• Cognitive assessment: Morris Water Maze testing at 28 days post-ICH for long-term functional outcome.

Core Findings and Why They Matter

The study's major findings are as follows:

• H3K18la is upregulated in microglia after ICH: Elevated H3K18 lactylation was observed in microglia in perihematomal regions, concurrent with increased OPC recruitment—a process linked to myelin repair.
• p300/CBP inhibition (A-485) decreases H3K18la, impairs OPC response, and exacerbates WMI: Suppressing the writer enzyme for lactylation led to reduced histone modification, fewer OPCs at the injury site, greater myelin loss, and worsened cognitive outcomes.
• Sodium oxamate aggravates WMI but does not significantly suppress microglial H3K18la or worsen cognition: Inhibiting LDH-A with oxamate led to more severe white matter damage, yet H3K18la levels in microglia were relatively preserved, and cognitive deficits were not exacerbated. This finding suggests that metabolic lactate is not the sole source or regulator of protective histone lactylation in microglia.
• Microglial depletion (PLX5622) worsens both WMI and cognitive impairment: Removing microglia mimicked the effects of p300/CBP inhibition, underlining microglia as cellular executors of the lactate-H3K18la axis.
• No additive effect with combined microglia depletion and A-485: This outcome supports the conclusion that p300/CBP-mediated lactylation in microglia is the relevant effector pathway.

Together, these results position lactate-derived H3K18la in microglia as an active, endogenous repair mechanism after ICH. The distinction between metabolic and epigenetic inhibition underscores the specificity of lactylation as a therapeutic target. The study also highlights microglia as a cell population central to white matter preservation and cognitive recovery.

Comparison with Existing Internal Articles

Several recent resources provide context for these findings:

• The article "Sodium Oxamate: Mechanisms, Evidence, and Research Protocols" supports the role of sodium oxamate as a robust LDH-A inhibitor in both cancer and neuroprotection models. Notably, it echoes the current study's conclusion that metabolic inhibition can worsen white matter injury independently of epigenetic effects.
• In cancer metabolism research, sodium oxamate is widely deployed to interrogate glycolytic flux and lactate-driven resistance mechanisms, as detailed in "Sodium Oxamate: Precision Tools for Cancer Metabolism Research". Here, the focus is on the anti-proliferative and pro-apoptotic effects mediated by blocking the Warburg effect, in contrast to the neuroprotective context of the current ICH study.
• Relatedly, "Histone H4K12 Lactylation Drives TNBC via SLFN5 Downregulation" demonstrates that histone lactylation modulates gene expression and disease phenotype in cancer, and that sodium oxamate can reverse these effects. This cross-disciplinary evidence underscores the broader relevance of lactate-derived epigenetic modifications in both oncology and neurology.

Collectively, the internal literature highlights sodium oxamate's utility as a metabolic reprogramming inhibitor and research tool, while reinforcing the emerging significance of histone lactylation in disease modulation.

Limitations and Transferability

While the findings illuminate a novel neuroprotective axis, several limitations merit consideration:

• Species and model specificity: The results are derived from a murine collagenase-induced ICH model, which may not fully recapitulate the complexity of human brain hemorrhage and repair.
• Pharmacological specificity: Although sodium oxamate is a validated competitive LDH-A inhibitor, its systemic effects and off-target actions in vivo warrant further investigation, especially in the context of long-term cognitive outcomes.
• Epigenetic-metabolic interplay: The partial dissociation between metabolic lactate inhibition and histone lactylation indicates that alternative lactyl-CoA sources or compensatory pathways may exist in microglia. This complicates efforts to modulate the pathway therapeutically.
• Temporal resolution: The study primarily focuses on the subacute to chronic phases post-ICH. Acute phase responses and longer-term neurodegenerative sequelae remain to be explored.

Thus, while the lactate-p300/CBP-H3K18la axis in microglia emerges as a promising therapeutic target, translation to clinical intervention will require further validation in diverse models and patient-derived systems.

Research Support Resources

For researchers aiming to interrogate glycolytic flux, metabolic reprogramming, or the role of lactate in neuroepigenetic regulation, sodium oxamate (Oxamic Acid) remains a gold-standard small molecule tool. Sodium Oxamate (SKU C3893) from APExBIO is widely validated for LDH-A inhibition and is suitable for protocols spanning cancer metabolism and neuroprotection studies. Its documented efficacy and solubility profile facilitate reproducible integration into white matter injury and tumor bioenergetics workflows, as reflected in both recent publications and detailed workflow guides. Always consult peer-reviewed literature and product documentation for dosing and experimental design alignment.